Corvese Brian 4
4 · MiNK Therapeutics, Inc. · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
MiNK Therapeutics Director Brian Corvese Receives RSU Award
What Happened
Brian Corvese, a director of MiNK Therapeutics, was awarded restricted stock units (RSUs) in two grants: 1,640 RSUs on 2026-03-02 at an attributable price of $10.90 each (value $17,876) and 1,444 RSUs on 2026-06-01 at $12.38 each (value $17,877). The awards are reported as acquisitions (code A) and were issued in lieu of cash board/committee retainers.
Key Details
- Transaction dates & values:
- 2026-03-02: 1,640 RSUs @ $10.90 = $17,876
- 2026-06-01: 1,444 RSUs @ $12.38 = $17,877
- Total: 3,084 RSUs, aggregate reported value ~$35,753
- RSU mechanics: Each RSU represents a contingent right to one share; vesting is scheduled one month after each grant date (per footnote F1).
- Filing/timeliness: The Form 4 was filed 2026-06-02; footnote F2 states the Q1 (3/2) RSUs were not filed timely (late filing).
- Shares owned after transaction: Not disclosed in the provided excerpt.
Context
RSUs are compensation awards that convert to shares on vesting and are common for board pay; they are not an open-market purchase and do not, by themselves, indicate trading sentiment. The late filing for the Q1 grant means the market received the disclosure after the grant and associated vesting window had begun.
Insider Transaction Report
- Award
Common Stock
[F2]2026-03-02$10.90/sh+1,640$17,876→ 51,693 total - Award
Common Stock
[F1]2026-06-01$12.38/sh+1,444$17,877→ 53,137 total
Footnotes (2)
- [F1]The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
- [F2]Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.